Hormonal Management for Transfeminine Individuals.

Area of Science:

• Endocrinology
• Reproductive Health
• Gender Affirming Care

Background:

• Transfeminine individuals often undergo hormone replacement therapy (HRT) to align physical characteristics with gender identity.
• Estradiol and anti-androgen medications are primary agents used in feminizing HRT.
• HRT aims to induce physical changes such as breast development and fat redistribution.

Purpose of the Study:

• To review the physical effects and potential risks of estradiol therapy in transfeminine individuals.
• To emphasize the importance of monitoring and dose adjustment in feminizing HRT.
• To outline the benefits and adverse outcomes associated with hormone therapy for transgender women.

Main Methods:

• Review of current medical literature on transfeminine hormone therapy.
• Analysis of physiological changes induced by estradiol.
• Examination of adverse effects and benefits reported in clinical studies.

Main Results:

• Estradiol therapy promotes feminization, including breast development, altered body fat distribution, and reduced muscle mass.
• Potential adverse effects include thromboembolic disease, macroprolactinoma, and cardiovascular issues.
• Hormonal treatment can lead to improved quality of life and reduced gender dysphoria.

Conclusions:

• Transfeminine hormone therapy requires careful management to optimize feminization and mitigate health risks.
• Regular monitoring and individualized dose adjustments are crucial for safe and effective treatment.
• While risks exist, the benefits of HRT, including psychological well-being, are significant for many transfeminine individuals.